Scribe Therapeutics
PrivateLast Round
Grant
Jun 18, 2026
Est. Valuation
$300M
Total Funding Raised
$175M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Scribe Therapeutics is a biotechnology company that develops engineered CRISPR technologies and genetic medicines aimed at treating genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Scribe Therapeutics Comparables
Compare Scribe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arbor Biotechnologies | 86% | |
| YolTech Therapeutics | 83% | |
| Epicrispr Biotechnologies | 82% |
Scribe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 18, 2026 | ||||
| Convertible Debt | May 16, 2023 | ||||
| Series B | Mar 31, 2021 | ||||
| Series A | Oct 6, 2020 |
Key People
Founding team and executive leadership
Scribe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Series A |
| RA Capital Management | Series B |
| Perceptive Advisors | Series B |
| Avoro Ventures | Series B |
| Avoro Capital | Series B |
| OrbiMed | Series B |
| T. Rowe Price | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 41% MoM to 17.8K.
- Jun 20, 2026
Monthly visitors grew 49% MoM, from 7.4K to 11K.
Recent news
Latest coverage and updates
- goes_publicJul 24, 2026
Scribe went public on Jul 24th '26.
- goes_publicJul 6, 2026
Scribe is planning to go public.
- receives_financingJun 19, 2026
Scribe received financing of $25M in funding on Jun 19th '26.
Scribe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Scribe Therapeutics's valuation, stock price, and market status.
Is Scribe Therapeutics a public or private company?
Scribe Therapeutics is a private company.
What is the current stock price of Scribe Therapeutics?
Scribe Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Scribe Therapeutics worth (valuation)?
Valuation information for Scribe Therapeutics is not publicly available.
Can I buy Scribe Therapeutics stock?
Scribe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Scribe Therapeutics's last funding round?
Scribe Therapeutics's most recent funding round was Convertible Debt on May 16, 2023.
Who are the main investors in Scribe Therapeutics?
Key investors in Scribe Therapeutics include Andreessen Horowitz, Avoro Ventures, Avoro Capital.
Will Scribe Therapeutics IPO soon?
No public IPO plans have been announced for Scribe Therapeutics.
How can I track Scribe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Scribe Therapeutics's secondary market activity and sign up for updates.